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Introduction
Nociceptin/Orphanin FQ (N/OFQ) is the endogenous peptide activator of the N/OFQ receptor (NOP), classified by IUPHAR as a non-opioid (or non-classical) member of the opioid family.
Since the discovery of NOP and its deorphanisation, N/OFQ-NOP system has revealed some intriguing pharmacology. Not least a dual action in pain processing with anti-opioid actions supraspinally and antinociceptive actions in the spinal cord [Halford et al., 1999; Lambert, 2008] . The vast range of additional peripheral actions for NOP activation have reinvigorated interest also regarding its immunomodulatory actions and effects on isolated airway tissues.
The increasing prevalence of asthma is a major health problem affecting 235 million worldwide with an annual mortality of ~0.25million [WHO, 2013] . Asthma is a complex heterogeneous and devastating disease characterised by variable degree of airflow obstruction, airway hyper-responsiveness, chronic airway inflammation and airway remodelling [Brightling et al., 2012] . These changes are the result of a crosstalk between resident structural airway smooth muscle (ASM) and epithelial cells, progenitors including fibrocytes, infiltrating airway submucosal inflammatory cells (eosinophils and T cells) , localised mast cells within ASM bundles and Th2 cells (and their cytokines) .
With respect to airways, NOP activation abolishes capsaicin-and electrical field stimulation (EFS)-induced contraction in guinea pig airways [Corboz et al., 2000; Shah et al., 1998 ] and EFS-induced contractions of an ex vivo human bronchial ring preparation [Basso et al., 2005] .
These effects have been attributed to inhibition of airway acetylcholine and sensory neuropeptide release [Corboz et al., 2000; Patel et al., 1997] . In ovalbumin (OVA)-sensitized mice, capsaicin induces increased airway hyperresponsiveness (AHR) that may be partly mediated by reduced endogenous N/OFQ. More significantly, N/OFQ inhibits capsaicininduced bronchoconstriction in both naïve and (OVA)-sensitized mice [D'Agostino et al., 2012] . In addition, NOP agonists are antitussive in preclinical models [McLeod et al., 2001] .
In a clinical setting, combined anti-inflammatory/bronchodilator therapy is effective in controlling asthma, however ~10% of asthmatics display variably steroid resistant patterns of inflammation [Bousquet et al., 2009] . Development of new therapies combining both bronchodilator and steroid free immuno-suppressor profiles offer several advantages over the current treatments not least a simplified dosing regimen.
We hypothesized that N/OFQ-NOP system plays a critical role in the pathogenesis of airway inflammation, airflow obstruction and hyperresponsiveness; hallmarks of asthma. There are currently no data on N/OFQ-NOP expression in cells from human airways and as such its potential role in human asthma is unknown. We have addressed this hypothesis by investigating NOP, ppN/OFQ mRNA and N/OFQ peptide expression and function within airway tissue. We have used ex vivo human tissue from phenotyped asthmatic and nonasthmatic patients and volunteers and compared data with an established in vivo ovalbumin(OVA)-sensitised mouse model of asthma. We show that N/OFQ is a candidate dual immunomodulator and bronchodilator.
Methods
Detailed methods are available in the Online Supplement.
Subjects
Asthmatic subjects and healthy controls were recruited in Leicester, UK and clinical characteristic are reported in Table 1 with the approval of the Leicestershire Ethics Committees. All patients gave written informed consent. Asthmatic subjects had a consistent history and objective evidence of asthma. Asthma severity was defined by Global Initiative for Asthma treatment steps (mild-moderate GINA 1-3, severe GINA 4-5). Subjects underwent extensive clinical characterization including sputum induction and video assisted fibreoptic bronchoscopic examination.
Cell isolation and culture
Pure human airway smooth muscle (HASM) bundles [Brightling et al., 2005] , primary human bronchial epithelial cells (HBEC) [Martin et al., 2011] and human lung mast cells (HLMC) [Sanmugalingam et al., 2000] were isolated and cultured as described. HMC-1(human mastocytoma cell line) and EOL-1(human eosinophil-like) cell lines were cultured, as described [Butterfield et al., 1990] . Peripheral blood eosinophils(PBEs) were isolated from heparinized peripheral venous blood from healthy control subjects and asthmatic volunteers using LS columns (Miltenyi Biotech-United Kingdom).
Membrane preparation and [ 125 I] radioisotope dilution assay
Membranes were prepared from freshly harvested cells, HASM (asthmatic and non-asthmatic) and HMC-1 cells at confluence. Cells were suspended in homogenising buffer of Tris-HCl (50mM), MgSO4 (5mM) pH7.4 with KOH and were homogenised followed by centrifugation at 13,500rpm, for 10min at 4°C. Membrane protein (20μg of CHO hNOP , 200µg
of HASM and HMC-1) was incubated in 0.5 ml of homogenisation buffer containing 0.5%
BSA, 10μM peptidase inhibitors (amastatin, bestatin, captopril, phosphoramidon-SigmaAldrich, Poole, UK) and various concentrations of 125 I-N/OFQ (~10pM -1nM, Perkin Elmer, UK) for 1h at room temperature. Nonspecific binding (NSB) was defined in the presence of 1μM unlabelled N/OFQ. Bound and free radioactivities were separated by vacuum filtration using a Brandel cell harvester onto Whatman GF/B filters. Filter-bound radioactivity was assessed by a gamma counter and receptor density was calculated from dilution isotherms.
Quantitative real time PCR (qRT PCR)
All airway and immune cells from volunteers and patients or cultured cells were prepared immediately or stored in RNAlater® (Ambion, Warrington, UK) before RNA extraction.
Total RNA was extracted and final RNA pellets (patient or cultured cells) were resuspended in PCR grade water. The mass of RNA was determined using an Eppendorf Biophotometer and RNA purity crudely assessed from the 260/280 nm ratio which was in the range of 1.9 to 2.1 for all samples using a nanodrop (Thermo Scientific, UK). Total RNA extracted was processed using Turbo DNA-free® kit and a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Warrington, UK) according to the manufacturer's instructions.
Quantitative RT-PCR assessed mRNA quantity using commercially available TaqMan® gene expression assays from Applied Biosystems for the human NOP receptor (Hs00173471_m1), human prepronociceptin (ppN/OFQ or ppNOC; Hs00173823_m1), human CCL11 (eoatxin-1; Hs00237013_m1), human CCL26 (eotaxin-3; Hs00171146_m1) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or β2 microglobulin (β2M). TaqMan probes for the genes under investigation and GAPDH contained different dyes and so were used in a duplex assay format. The thermal profile for quantitative real-time PCR (Q-PCR) reactions in the
StepOne instrument (Applied Biosystems) was 2min at 50°C, 10 min at 95°C, 40 or 50 cycles of 15 s at 95°C, and 1 min at 60°C. Non-template controls were included for all samples.
Results were expressed as ΔCt: the difference in cycle threshold (Ct) of the gene of interest and the housekeeper gene, GAPDH or β2 microglobulin. Typical methodology is further described in [Leonard et al., 2009] .
Immunohistochemistry
Sequential 2μm sections were cut from glycomethacrylate embedded asthmatic and healthy bronchial biopsies and stained using a polyclonal anti-human nociceptin/orphanin FQ antibody (1 in 200 dilution, Phoenix Europe GmbH, Germany), and appropriate isotype control rabbit IgG (Phoenix Europe GmbH, Germany). N/OFQ staining in airway smooth muscle was assessed using a semi-quantitative score of no staining=0, very low=1, low=2, moderate=3, high=4, and very high=5.
Cell Migration
24-well or 96-well Transwell migration assay was used to measure the migration of HMC-1 cells, HLMCs, EOL-1 cells and peripheral blood eosinophils in response to chemoattractants.
To investigate mast cell migration, 450μL of SCF (10ng/ml, R & D Systems, Abingdon, UK), CXCL10 (10ng/ml, R & D Systems, Abingdon, UK) and human airway smooth muscle supernatants stimulated with recombinant TNF-α for 24hours (10ng/ml, R & D Systems, Abingdon, UK) were used as chemoattractants. We used epithelial conditioned media (ECM) and sputum from severe asthmatic volunteers (with very high levels of N/OFQ) as chemoattractants to study peripheral blood eosinophil and EOL-1 cell migration.
Chemoattractants were added to the bottom compartment of each well, with the exception of the negative controls. Cells were then added to the top chamber of each well (2. 
Measurement of IL8 release from HMC-1 cells
HMC-1 cells were grown in 6-well culture plates and then pre-incubated in the presence or absence of N/OFQ (300nM) for 60minutes at 37°C in the presence of peptidase inhibitors.
Next cells were stimulated in the presence or absence of SCF (10ng/ml, R & D Systems, Abingdon, UK for 24hours at 37ºC. After 24h, supernatants were collected, centrifuged at 1500rpm for 5minutes to remove debris and stored at -80ºC till further analysis. IL-8
concentrations were determined using a DuoSet ELISA Development kit from R&D Systems.
Wound healing
Non-asthmatic and asthmatic HBEC cells were seeded onto 8-well culture plates, serum deprived for 24h, and then wounded using a sterile 200-μl pipette tip in a predetermined grid pattern. After wounding cells were washed and treated in the presence or absence of N/OFQ (3nM and 300nM). Non-asthmatic and asthmatic HASM cells were seeded onto 8-well fibronectin-coated plates, serum deprived for 24h in ITS medium, and then wounded using a sterile 200-μl pipette tip in a predetermined grid pattern. After wounding HASM cells were washed and treated in the presence or absence of N/OFQ (3nM, 30nM and 300nM). Wounds were then photographed at baseline, after 6 h and 24 h. Wound areas were analyzed by a blinded observer using Image J software and the extent of repair calculated and expressed as a percentage of wound healed area.
Sputum N/OFQ measurement by RIA
Acidified sputum samples were extracted using Strata C18-E solid-phase extraction cartridges with eluate. N/OFQ measured by RIA as described [Williams et al., 2008] .
Assessment of airway smooth muscle contraction by Collagen Gel Analysis
Contractile properties of airway smooth muscle cells were assessed using collagen gel contraction assay. Collagen gels were impregnated with HASM cells (2.5x10 5 cells) resuspended in DMEM with Glutamax-1 supplemented with penicillin (100U/mL), streptomycin (100μg/mL), amphotericin (0.25μg/mL), non-essential amino-acids (100μM) (Invitrogen), sodium pyruvate (1mM) and insulin-transferrin-selenium (1%) (Sigma). Next 450μL of gel mixture was added to each well of a PBS 2% BSA pre-coated 24-well plate and allowed to polymerize at 37°C for 90min. After polymerization, 500μL DMEM with Glutamax-1 (supplemented as above) was added to each well and the gel was detached from the plastic surface to allow free contraction. Collagen gels were then incubated in the presence or absence of N/OFQ (3nM and 300nM) for 24hours at 37°C. Carbachol (100µM) or bradykinin (10nM) were then added to each well in an equal volume of the above media.
The collagen gels were photographed at specified time points over a 3h period by a blinded observer and the gel size as a percentage of the well area was calculated at specific time points using ImageJ software (National Institutes of Health, USA). All gel conditions were performed in duplicate.
ANIMAL STUDIES
All experimental procedures were in accordance with Italian DLgs 26/2014, application of the EU Directive 2010/63/EU.
Experimental protocol
Female BALB/c mice were used in this study. Animals were sensitized to ovalbumin (OVA) by subcutaneous (s.c.) injection with 0.4 ml of 10μg OVA, absorbed to 3.3mg of aluminium hydroxide gel in sterile saline at day 0 and 7. From day 21 to 23, all OVA sensitized mice were aerosol-challenged (7-minutes long daily sessions) with 1% ovalbumin in phosphatebuffered saline using an ultrasonic nebulizer (De Vilbiss Health Care, UK Ltd., Heston, Middlesex, UK). We used untreated animals (naïve mice) and OVA sensitized mice, treated 
Airway hyperresponsiveness
AHR to acetylcholine was assessed in an isolated and perfused mouse lung model as described in detail in [Roviezzo et al., 2007] . After 60 min, mean tidal volume was 0.21±0.02ml (n=61), mean airway resistance 0.23±0.08 cmH 2 Os ml −1 , and mean pulmonary artery pressure 2.9±1.4cmH 2 O. The measured airway resistance was corrected for the resistance of the pneumotachograph and the tracheal cannula of 0.6cmH 2 Os ml −1 .
Bronchoalveolar lavage
Mouse BAL fluid was collected as follows: 1.5 ml of saline was instilled and withdrawn from the lungs via an intratracheal cannula; this lavage was performed three times, and different samples were collected. Bronchoalveolar lavage fluid was centrifuged at 1000 g for 10 min at 4 °C. The supernatant was transferred into tubes and stored at −70 °C before use to analyze the cytokine production. Cell pellets were resuspended in phosphate-buffered saline to a final volume of 0.5 ml for total and differential cell counting.
Total and differential cell count
Total cell count was performed using the Countess automated cell counter (Invitrogen), which evaluates cell number and viability using trypan blue stain according to the manufacturer's instructions. Differential counting was performed on Diff-Quik (Reagena, Invitrogen, Milan, Italy) as detailed previously [Vignali, 2000] . All samples were run in duplicate. Data were analyzed using Xponent software (1.9 version, Luminex® 200™ System, Invitrogen, Milan, Italy).
Histochemistry and immunofluorescence
Lungs were perfused and fixed in 10% phosphate-buffered formalin. Tissue was embedded in paraffin and cut in 5μm sections for histological analysis. For immunofluorescence, after deparaffinization and rehydration, tissue sections were treated with 10% normal donkey serum for 30min. at room temperature and then incubated with the primary antibodies diluted 
Measurement of OVA-specific IgE and IgG levels in BAL fluid by ELISA
Briefly, BAL fluid samples were mixed with an equal volume of trifluoroacetic acid (TFA: 1% v:v). Acidified samples were then loaded onto Strata C18-E solid-phase extraction cartridges and washed twice with 0.1% TFA. Samples were eluted with 0.1 % TFA 3ml 60%
acetonitrile, lyophilised using a centrifugal evaporator and then freeze dried. Before assay, the sample was reconstituted in assay buffer. OVA-specific IgE (Cambridge Bioscience, UK; assay range 20.7 pg/ml -20ng/ml) and OVA-specific IgG (2B Scientific, Oxford, UK, assay range 1.56 U/ml -100 U/ml) ELISA was performed according to the manufacturer's protocol.
Statistical Analysis
Analysis between groups was performed (PRISM Version 6 (GraphPad, CA) by paired or unpaired t-tests and across groups by one-way / two-way ANOVA with appropriate post hoc comparisons. Post hoc tests were only performed if F was significant. Due to the limitations in the availability of tissue material, some animal and human studies were performed with n<5. However no statistical analysis was performed for sample sizes less than 5. For sputum N/OFQ measurements, subjects were categorized into three groups: healthy, mild/moderate asthmatics (GINA1-3) and severe asthmatics (GINA4-5). Between group differences were analysed by unpaired t-tests or Fisher's exact test. Correlations were assessed by Spearman rank (rs) coefficients. Values of p<0.05 was considered significant.
Results

N/OFQ expression in asthmatic human airways and blood eosinophils.
Severe asthmatics (GINA4-5) had significantly higher levels of N/OFQ in sputum relative to healthy volunteers and GINA1-3 subjects ( Figure 1a ). There was no statistical difference between levels of N/OFQ in the sputum from healthy and asthmatic (mild-mod). Although N/OFQ and FEV 1 /FVC did not correlate ( Figure E1 online supplement), we observed a weak correlation between the increased number of eosinophils in asthmatic patients (mild-moderate and severe) and sputum N/OFQ ( Figure 1b , Table 1 ). In a search for the source of N/OFQ peptide we assessed its expression in human airway tissue using IHC. N/OFQ staining appeared to be increased in asthma biopsies with a preferential sub-epithelial and extracellular matrix location and a weak staining in HASM bundles (Figure 1c, d) . These observations are consistent with sputum measurements and indicate that the eosinophils potentially release N/OFQ within the airways. In fact, ppN/OFQ mRNA transcripts were found in peripheral blood eosinophils (PBE), but not in human airway structural cells, from healthy (expression observed in 5/9 independent samples;ΔCт = 21.73±1.57) and asthmatic (expression observed in 5/7 independent samples;ΔCт = 18.31±2.66) patients with no statistically significant differences (p<0.05; Figure 1e ).
NOP receptor expression on HLMCs, HMC-1 and airway structural cells
Interestingly, HLMCs and HMC-1 cells expressed higher levels of NOP mRNA transcript than HASM cells and HBECs. NOP mRNA transcript was also detected in EOL-1 (eosinophil like) cells and native eosinophils isolated from the peripheral blood of healthy and asthmatic volunteers. In contrast to N/OFQ, no differences were observed between healthy and asthmatic subjects documenting no disease signal (Figure 1f) . Additionally, in a series of [125] I N/OFQ radioligand isotope dilution assays, cell membrane NOP receptor density was quantified on HASM (B max ;7.3±1.1 fmol/mg protein,n=9) and HMC-1 cells (B max ;17±5.9 fmol/mg protein,n=3). NOP receptor density was significantly increased in Overall, these data demonstrate that N/OFQ-NOP system is not only present in human airways but may also have a role in asthma as suggested by increased N/OFQN/OFQ-NOP system may be positively involved in airway pathophysiology, we therefore considered whether the concentration was insufficiently increased to completely ameliorate inflammation in vivo and whether an additional exogenous N/OFQ supplement is required to induce beneficial effects.
Exogenous N/OFQ improves functional parameters and reduces inflammation in experimental allergic asthma.
To investigate the impact of exogenous N/OFQ on allergic asthma, N/OFQ was administered in mice prior to allergen sensitization or during the challenge period to examine effects on [Nilsson et al., 1999; Olsson et al., 2004] . SCF-stimulated IL-8 release from HMC-1 cells was significantly inhibited by N/OFQ (Figure 6d ). However there was no effect on TNF-α release ( Figure E6 online supplement).
CCL11 and CCL26 are involved in the activation and recruitment of PBEs [Garcia-Zepeda et al., 1996; White et al., 1997] . N/OFQ treatment demonstrated a trend towards reduced (increased ΔCt). TNF-α stimulated CCL11 mRNA expression in HASM (Figure 6e ) and TNF-α stimulated CCL11 release appear to be inhibited by N/OFQ (Figure 6f ). N/OFQ treatment appeared to reduce IL-13 stimulated CCL26 mRNA transcript and protein expression in HBEC (Figure 6g and 6h) .
N/OFQ promotes wound repair of human airway structural cells but has no effect on cell proliferation.
Features of airway remodelling include epithelial cell damage and mucus hypersecretion.
Airway epithelial repair is regulated through proliferation, migration and differentiation of cells adjoining the damaged area [Tam et al., 2011] .
To test the effects of N/OFQ on repair capacity of bronchial epithelium, confluent monolayers of undifferentiated healthy and asthmatic HBEC were scratch-wounded in the 
Discussion
Using a combination of complementary in vitro human and in vivo mouse studies, we showed that AHR, eosinophil and mast cell migration and inflammatory mediator release in the lungs were dramatically inhibited by N/OFQ. This is the first study to report a critical role for this system in asthma and describes a novel agent with combined anti-hyperresponsivness and immunomodulatory properties.
There is emerging evidence suggesting a generalised immunomodulatory role for the N/OFQ-NOP system [Miller and Fulford, 2007] and our data showed that asthmatic sputum had significantly elevated levels of N/OFQ. This may come from the increased eosinophil counts as there was a correlation between increased eosinophils and elevated N/OFQ. N/OFQ inhibited eosinophil and mast cell migration and attenuated the release of inflammatory mediators that play key roles in their recruitment. Interestingly, N/OFQ expression was found to be up regulated in the lung biopsies from asthmatic patients. In particular, N/OFQ was increased in sub-epithelial layer and extracellular matrix. We also demonstrated significant NOP expression in human airway structural and inflammatory cells with ppN/OFQ expression only in eosinophils. However, we did not detect any significant increase in NOP expression in asthma implying no disease signal. Functional in vitro studies showed that N/OFQ significantly inhibited agonist-induced HASM-embedded gel contraction and we hypothesise that this could be an additional effect to its anti-inflammatory role; a response that requires further investigation.
Asthmatic sputum contains several cytokines and chemokines that regulate eosinophil migration including IL-5, IL-8, RANTES, IgA and complexes of IL-8-IgA [Louis et al., 1997] . The increase in the levels of endogenous N/OFQ in sputum (~8-19 pM; 15-35pg/ml) of asthmatic patients was several orders of magnitude lower than that required to exert beneficial effects in vitro. We therefore suggest that additional exogenous N/OFQ administration in the airways might present a new therapeutic strategy for asthma. This hypothesis is supported by our observation that spiking sputum from severe asthmatics (with reported high levels of endogenous N/OFQ) with additional N/OFQ (30 nM and 300 nM), which is over 2000-fold higher than measured endogenously, significantly attenuated migration of eosinophils towards asthmatic sputum.
N/OFQ is a naturally occurring peptide and does not cross the blood brain barrier [Lambert et al., 2008] and no significant adverse effects were reported in clinical trial evaluating the urodynamic effects of intravesical administration of 1 μM N/OFQ in patients with neurogenic detrusor activity [Lazzeri et al., 2003] . Therefore, any systemic/local administration of N/OFQ is unlikely to induce any unwanted central effects.
As a proof of concept, our in vivo experiments confirmed the hypothesis that exogenous N/OFQ can ameliorate the course of asthma. OVA sensitization followed by challenge has been widely used as a model of airway inflammation although this may not entirely reflect human asthma pathology. It does, however retain many features of human allergic asthma including Th2 cytokine production, goblet cell hyperplasia, mast cell degranulation, IgE production, AHR and airway remodelling [Gelfand, 2002; Kumar and Foster, 2002; Kumar et al., 2008; Han et al., 2013] . We found a significant reduction of allergen-increased levels of IL-4, IL-5, IL-12 and IL-13; Th2 cytokines linked to inflammation .
These observations were consistent with previous reports demonstrating inhibition of IL-2 release and T cell proliferation by N/OFQ [Miller and Fulford, 2007; Easten et al., 2009] .
Surprisingly, we did not observe any significant effect of N/OFQ on IFN-γ production, that is the principal effector of Th1-mediated inflammation and has a protective effect against Th2 driven immune responses [Teixeira et al., 2005] . Additionally, N/OFQ was able to inhibit levels of OVA-specific IgE in BAL fluid. However, it failed to modulate OVA-specific IgG levels. These observations suggest a Th2 selective immunomodulatory effect of N/OFQ in vivo.
Of note, we have administered N/OFQ either prior to or concurrent with OVA; this has important consequences for potential treatment paradigms. The observation that N/OFQ has efficacy in both models indicates that use in a clinical setting could involve both prophylaxis and control of acute symptoms. These data confirm and extend our recent study with the highly selective non-native NOP agonist UFP-112 [Sullo et al., 2013] .
One of the characteristic features of airway remodeling is epithelial cell damage. Abnormal epithelial shedding in asthmatic patients with a variable degree of epithelial damage has been observed [Liu et al., 2013] . Repair of airway epithelium is regulated through proliferation, migration and differentiation of cells adjoining the damaged area [Tam et al., 2011] .
Glucocorticoids, one of principal drug classes used in asthma, play a key immunomodulatory role in airway inflammation and provide a sustained repair potential for mechanically injured human airway epithelial cells [Barnes, 2002; Wadsworth et al., 2006] . However, studies have also shown that steroids can adversely affect the repair process by suppressing early-stage migration and proliferation of airway epithelial cells [Liu et al., 2013; Wadsworth et al., 2006] . Therefore, to identify a role for N/OFQ in repair, we explored the effect of this peptide on HBEC and HASM cell wound healing. We observed a significant up regulation in wound repair that relates more to lung cell homeostasis than immunomodulation. Importantly, this effect was predominant in cells from asthmatic airways. Additionally, N/OFQ reduced mucus production in vivo.
An important issue in chronic treatments is GPCR signalling desensitisation due to persistent ligand binding at high doses. NOP receptor signalling is regulated by the process of homologous desensitization [Donica et al., 2013] . Several factors are known to regulate this process including NOP receptor density, dose and duration of exposure, peptide and nonpeptide agonists. Acute exposure to its agonist N/OFQ, does not induce NOP receptor down regulation [Dautzenberg et al., 2001 ]. However, long-term exposure to N/OFQ differentially induces down-regulation in a time-dependent manner [Hashimoto et al., 2002] . Our in vitro assays demonstrate beneficial effects of N/OFQ at 3nM, 30 nM and 300 nM following administration of a single-dose for either 4 hours or 24 hours. It would therefore be interesting to investigate whether this N/OFQ administration regimen would result in NOP desensitisation. Another interesting observation would be to determine whether this would activate any compensatory mechanism(s) to maintain NOP receptor expression.
The main limitations of our study relate to lack of antagonist data and mechanistic information. Use of the antagonist UFP-101 in several other studies is questionable as it may have partial agonist activity [Mahmoud et al., 2010] making interpretation problematic.
Mechanistic details would be useful in particular the role of downstream signalling events in the N/OFQ-NOP system including calcium channel modulation, activation of protein kinase C, MAP kinase, extracellular signal regulated kinase 1/2 and Rho kinases; this would need further investigation [Baiula et al., 2013] . Despite these limitations, key strengths of our findings include consistency of the observations between human data and an animal model and the magnitude of the effects observed. The anti-inflammatory effects upon eosinophilic inflammation in the in vivo model are larger than typically observed with corticosteroids [Lee et al., 2008] and are similar to IL5 neutralisation [Leckie et al., 2000] . The magnitude of the effect upon cell migration was also larger than observed in response to corticosteroids or any anti-inflammatory therapy we have investigated . The effect upon airway hyper-responsiveness in vivo was similar to those described for anti-IL13 and anti-IL17 [Yang et al., 2004; Kinyanjui et al., 2013] , but the effect upon inhibiting in vitro agonist-induced airway smooth muscle contraction was the largest.
Clinical translation of this data set is a critical future development but clearly there are 'non therapeutic' issues with N/OFQ as it is a natural product already in the public domain.
Supraspinal NOP activation has the potential to produce hyperalgesic/antiopioid effects [Schröder et al., 2014] Our data suggest that endogenous N/OFQ is elevated in asthma but its concentrations are too low to substantially modulate the immune system and airway hyperresponsiveness indicating that the supplementation with exogenous N/OFQ is needed.
In conclusion, we have identified an important and an innovative role for N/OFQ in counteracting non-neurogenic airway inflammatory responses and airwayhyperresponsiveness. This combination of beneficial effects is rarely observed and supports our assertion that this opens a completely new potential target/strategy in the treatment of asthma. 2 (22) 7 (78) 12 (40) 2 (17) 10 (83) 16 (29) 3 (19) 13 (81) 0.99
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# 3.9 ± 1.5 6.3 ± 1.9 4.5 ± 1.2 0.60 Table I : Clinical characteristics of healthy and asthmatic volunteers recruited for sputum analysis. # Mean ± SEM; * Median (interquartile range). P value represents comparisons between healthy subjects and GINA 4-5 patients. (a) Sputum N/OFQ levels from healthy (n=29 subjects; n=5 below detection limit), mild to moderate asthmatic (GINA1-3; n=30 patients;, n=7 below detection limit) and severe asthmatic (GINA 4-5; n=55 patients; n=2 below detection limit) donors, (b) Correlation between sputum N/OFQ (pg/ml) and sputum eosinophils (%) in asthmatics (mild-moderate 
Materials and Methods (for experiments in supplement)
Cell isolation and culture Pure human airway smooth muscle (HASM) bundles were isolated from biopsies obtained at bronchoscopy and from lung resection from well-characterised asthmatics and healthy volunteers. HASM cells were cultured in DMEM with Glutamax-1 supplemented with 10% FBS, 100U/mL penicillin, 100nicillin, 100mycin, 0.25 and healthy volunteers. HASM cells were cultured in DMEM with Gum pyruvate. HASM cell characteristics were determined by immunofluorescence and light microscopy with α-smooth muscle actin-FITC direct conjugate (Sigma, Gillingham, Dorset, UK). Primary human bronchial epithelial cells (HBEC) were isolated from bronchial brushes, and grown to confluence on 1% PureCol-coated surfaces (Inamed Biomaterials, Nutacon, The Netherlands) as submerged cultures using bronchial epithelial growth medium (BEGM, Lonza Verviers, Belgium) supplemented with 0.3% Fungizone, Belgium) su (Gibco, Invitrogen, Paisley, UK) and 1% antibiotic-Antimycotic (AA) (Gibco).
Human lung mast cells (HLMC) were dispersed from macroscopically normal lung obtained within 1h of surgical resection for lung cancer using immunoaffinity magnetic selection as described previously. Mast cell purity and viability were tested and typically >95% were observed to be pure and viable. HLMCs were then cultured in DMEM, 10% FBS, antibiotic/antimycotic solution, SCF (100ng/ml), IL-6 (50ng/ml) and IL-10 (10ng/ml). The HMC-1 cell lines were cultured in Iscove's medium containing 10% iron-supplemented fetal calf serum and 1.2mM-thioglycerol. Cells were split 1:10 every 3 days and resuspended in fresh medium. EOL-1 (eosinophil-like) cells were cultured in RPMI media supplemented with 10% FBS and antibiotic/antimycotic solution.
Isolation of eosinophils from peripheral blood
Eosinophils were isolated from heparinized peripheral venous blood from healthy control subjects and asthmatic volunteers. Briefly, 30-40mL of peripheral blood was collected and layered on top of an equal volume of Polymorph prep solution (Axis-Shield Point-of-Care Division, Oslo, Norway). This was then centrifuged at 600g for 45minutes at 20 o C. The polymorphonuclear cell layer was isolated, mixed with an equal volume of PBS and centrifuged at 600g for 10minutes at 20°C. Supernatant was then discarded and red blood cells in the cell pellet were lysed with cell lysis buffer (BD Biosciences, UK) by incubating for 15minutes at room temperature. Red blood cells were discarded following centrifugation at 600g for 10minutes at 20°C. Next eosinophils were negatively selected by using neutrophil-specific anti-CD16c anti-CD16emicrobeads and LS columns (Miltenyi Biotech, Surrey, United Kingdom). Finally, purity was assessed with Kimura stain. Eosinophil purity was consistently >95% and the viability of freshly isolated eosinophils was >99% as evaluated by Trypan blue dye exclusion.
Proliferation Assays
HMC-1 cells were grown at a density of 1e e 5 cells per well in 6-well culture plates in their normal growth medium until they achieved 70 % confluency. Later cells were serum starved for 24 hours and then incubated with SCF (10ng/ml) or 10% FBS supplemented DMEM media in the presence or absence of N/OFQ (300nM) for either 24 or 48hours. Cells were then harvested and counted with a haemocytometer by a blinded observer. In addition, MTS proliferation assay was performed using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt, according to the manufacturer's instructions (Promega, Southampton, UK). HMC-1 cells were cultured at a density of 1ty 4 cells per well in 96-well culture plates until the cells achieved 70% confluency. Next cells were serum starved for 24hours and then incubated with SCF (10ng/ml) or 10% FBS supplemented DMEM media in the presence or absence of N/OFQ (300nM) for either 24 or 48hours. Next, 20μL of CellTiter 96 Aqueous One Solution Reagent (Promega, Southampton, United Kingdom) was added to each well. After 4hours in culture, the cell viability was determined by measuring the absorbance at 490nm with a Multiskan* Ascent Microplate Photometer (ThermoFisher Scientific, UK). Results were expressed as fold change over the control (meanenti).
HASM/HMC-1 co culture proliferation assay HASM (non-asthmatic and asthmatic) were seeded onto 6-well plates at a density of 16x10 4 and grown in DMEM media containing 10% FBS, 1% antibiotic/antimycotic, 1% nonessential amino acids, and 1% sodium pyruvate till the cells achieved complete confluency. Cells were then serum starved for 24hours in DMEM media containing ITS (insulin, transferrin and selenium), 1% antibiotic/antimycotic, 1% nonessential amino acids, and 1% sodium pyruvate. Because analysis of bronchial biopsies reveal a mean mast cell density in asthmatic ASM bundles of ∼4 HASM cell:1 mast cells, 4ds, 4 HMC-1 cells were then seeded onto confluent HASM cells in the presence or absence of N/OFQ (300nM) for 48hours. Cell numbers during the culture period was assessed with a haemocytometer by a blinded observer using Kimura staining, which readily differentiates red metachromatic mast cells from unlabeled ASM cells. Results were expressed as fold change over the control (meana bl).
[ 3 H] thymidine incorporation in intact cells
Human ASM cells were cultured in 24-well plates in duplicate at a seeding density of 2.5X10 4 cells/ well at 37re cultur 2 in DMEM medium supplemented with 10% FBS, 1% antibiotic/antimycotic, 1% nonessential amino acids, and 1% sodium pyruvate. Subconfluent cultures (60-70%) were washed and then incubated in DMEM containing 0.1% FBS, 1% antibiotic/antimycotic, 1% nonessential amino acids, and 1% sodium pyruvate for 30h to growth arrest the cells. Platelet derived growth factor (PDGF-AB, Sigma-Aldrich, Poole, UK) at a concentration of 20ng/ml was then added for 16h in the presence or absence of N/OFQ (300nM) along with 1µM of peptidase inhibitors (amastatin / bestatin / phosphorhamidon / captoril). [ 3 H]thymidine (0.5idine (0.55/ captoril). [. [orill 24h of the incubation. At the end of this period, the supernatant was aspirated, and the cells were washed with PBS and lysed with 500μl of 0.4M percholic acid. Four hundred microliters of the supernatant were transferred to a scintillation vial along with 4.5ml of scintillation fluid and counted using liquid scintillation spectroscopy, the results being expressed as fold change over the control value. Proliferation rates were calculated as fold change over control and expressed as meand. F.
Measurement of cAMP formation
Confluent HMC-1 or HASM cell cultures (grown in T125 flasks) were incubated in 0.3ml Krebs buffer containing 0.5% BSA, 1mM isobutylmethylxanthine (IBMX) and forskolin (1skolin (1forskolin (1IBMX) and forskolin (1n T125 flasks) were incubeactions were terminated using 10M HCl and neutralised with 10M NaOH/1 mM Tris, pH7.4. The concentration of extracted cAMP was measured using a protein-binding assay against known cAMP standards. Results were calculated as fold change over basal and expressed as mean±SEM.
ANIMAL STUDIES
Measurement of airway hyperresponsiveness
Lungs were perfused in a non-recirculating fashion through the pulmonary artery at a constant flow of 1 ml/min resulting in a pulmonary artery pressure of 2-3 cm H 2 O. The perfusion medium used was RPMI 1640 lacking phenol red (37irculating fashion through the pulmonary artery at a constant flow o 2 O) with 90 breath min -1 and a tidal volume of about 200irculating fashion through the pulmonary a 2 O) was performed. Artificial thorax chamber pressure was measured with a differential pressure transducer (Validyne DP 45-24) and airflow velocity with pneumotachograph tube connected to a differential pressure transducer (Validyne DP 45-15). The lungs respired humidified air. The arterial pressure was continuously monitored by means of a pressure transducer (Isotec Healthdyne) which was connected with the cannula ending in the pulmonary artery. All data were transmitted to a computer and analysed with the Pulmodyn software (Hugo Sachs Elektronik, March Hugstetten, Germany). The data were analysed through the following formula: P= Vla -1 + R L · Rrou -1 , where P is chamber pressure, C pulmonary compliance, V tidal volume, R L airway resistance. The airway resistance value registered was corrected for the resistance of the pneumotacometer and the tracheal cannula of 0.6 cm H 2 O s ml -1 . Lungs were perfused and ventilated for 45 min without any treatment in order to obtain a baseline state. Subsequently, lungs were challenged with acethylcoline (10 -8 -10 -3 M). Repetitive dose response curve of acethylcoline was administered as 50sponse curve of or 45 min without any treatment in order to obtain a baseline state. Subse 3 H] thymidine incorporation was measured in HASM cultures stimulated with platelet-derived growth factor (PDGF-AB, 20 ng/ml) for 24 h in the presence or absence of N/OFQ expressed as actual counts, (d) MTS colorimetric assay was performed to detect HMC-1 cell viability and proliferation following stimulation with stem cell factor (SCF, 10 ng/ml) for 24 h in the presence or absence of N/OFQ expressed as actual counts. All data represent mean ± SEM (n=6 independent experiments). Comparisons made by one-way ANOVA. *p<0.05.
